Close Menu

Tekmira

Ian Mortimer has been named chief financial officer of biopharmaceutical firm Xenon.
Mortimer previously served as CFO of Tekmira Pharmaceuticals. Before that, he was CFO of Tekmira predecessor Inex Pharmaceuticals.

Researchers from Tekmira Pharmaceuticals last week published new data showing that siRNAs targeting Marburg virus that have been formulated with the company's lipid nanoparticles could provide up to 100 percent post-exposure protection against infection in guinea pig models.

Tekmira Pharmaceuticals this week announced that Spectrum Pharmaceuticals, which licensed Tekmira's non-RNAi cancer drug Marqibo earlier this year, has launched the product in the US.

Officials from Alnylam Pharmaceuticals last week provided updates on the company’s pipeline programs, highlighting efforts involving its GalNAc conjugation technology, which enables subcutaneous siRNA delivery, and a fledgling effort in complement-mediated diseases.

Tekmira Pharmaceuticals announced this week that it has launched a phase I/II clinical trial of its siRNA-based cancer therapy TKM-PLK, focusing on two forms of cancer that were particularly responsive to the drug in a previous study.

Tekmira Pharmaceuticals has appointed Mark Kowalski as its chief medical officer.
Before joining Tekmira, he was chief medical officer of YM BioSciences. He joined Gilead Sciences following its acquisition of YM.

Title: Dock-and-Lock Complexes for Delivery of Interference RNA
Patent Number: 8,491,914
Filed: Dec. 9, 2010
Lead Inventor: Chien-Hsing Chang, IBC Pharmaceuticals

Tekmira Pharmaceuticals this week announced that Talon Therapeutics, which licensed certain of the company’s legacy, non-RNAi drug candidates, will be acquired by Spectrum Pharmaceuticals.

Title: Nucleic Acids Involved in Viral Infection
Patent Number: 8,481,506
Filed: Dec. 5, 2007
Lead Inventor: Isaac Bentwich, Rosetta Genomics

Title: microRNA Expression in Human Peripheral Blood Microvesicles and Uses Thereof
Patent Number: 8,455,199
Filed: Sept. 12, 2008
Lead Inventor: Clay Marsh, Ohio State University

Pages

The US Patent and Trademark Office is opening another interference proceeding in the CRISPR patent fight.

There's increasing genetic evidence that a number of ancient hominins may have contributed to the human gene pool, according to Discover's The Crux blog.

The Japan News writes that Japan needs to seize the opportunity to ensure that a wide number of people benefit from personalized cancer treatments.

In Cell this week: messenger RNA expression and translation, RNA localization atlas, and more.